盐酸美法仑光降解杂质的鉴定与含量测定

陈雪琴; 高芳; 廖明毅; 李瑞; 李薇; 丁黎

doi:10.11665/j.issn.1000-5048.20170514

盐酸美法仑光降解杂质的鉴定与含量测定

陈雪琴^1,2,
高芳²,
廖明毅²,
李瑞²,
李薇²,
丁黎¹

1.
中国药科大学药物分析系
2.
江苏先声药业有限公司

计量
- 文章访问数: 1134
- HTML全文浏览量: 0
- PDF下载量: 1490
出版历程
- 刊出日期: 2017-10-24

Identification and determination of the photodegradation impurities in melphalan hydrochloride

摘要

摘要: 对盐酸美法仑的光降解杂质PD1和PD2进行结构鉴定，并对PD1和PD2建立含量测定方法。通过LC-MS/MS法推测光降解杂质的结构，合成相应杂质，通过杂质比对确认光降解杂质。建立亲水作用色谱法对PD1和PD2进行含量测定，色谱柱为Atlantis HILIC柱(4.6 mm×150 mm，3 μm)，流动相为0.1 mol/L甲酸铵溶液(甲酸调pH为3.0)-乙腈(13∶87)，流速为1.0 mL/min，柱温为35 ℃，检测波长为260 nm。结果显示:光降解杂质PD1为4-氨基-L-苯丙氨酸盐酸盐，PD2为4-(2-氯乙基氨基)-L-苯丙氨酸盐酸盐；在建立的亲水作用色谱法中，盐酸美法仑与PD1、PD2可完全分离，建立的方法可用于光降解杂质的含量测定。
- 盐酸美法仑 /
- 光降解杂质 /
- 结构鉴定 /
- 亲水作用色谱 /
- 含量测定
Abstract: This study was aimed to identify the photodegradation impurities(PD1 and PD2)in melphalan hydrochloride and establish a method for determining PD1 and PD2. The structures of the photodegradation impurities were inferred by LC-MS/MS. The impurities were confirmed by comparing with synthesized impurities. An HILIC method was established to determine PD1 and PD2. The method was carried out on an Atlantis HILIC column(4. 6 mm×150 mm, 3 μm)with the mobile phase consisting of 0. 1 mol/L ammonium formate(adjusted to pH 3. 0 with formic acid)and acetonitrile(13∶87)at the flow rate of 1. 0 mL/min. The column temperature was 35 °C. The detection wavelength was 260 nm. PD1 and PD2 were characterized as 4-amino-L-phenylalanine hydrochloride and 4-(2-chloroethyl)amino-L-phenylalanine hydrochloride, respectively. Melphalan hydrochloride, PD1 and PD2 were separated completely under the HILIC condition. The established HILIC method can be used to determine the photodegradation impurities.
- melphalan hydrochloride /
- photodegradation impurities /
- structural identification /
- hydrophilic interaction liquid chromatography(HILIC) /
- determination

HTML全文

参考文献(10)

[1]	Bogomilova A,Höhn M,Günther M,et al.A polyphosphoester conjugate of melphalan as antitumoral agent[J].Eur J Pharm Sci,2013,50(3):410-419.
[2]	Patel K,Parmar S,Shah S,et al.Comparison of subcutaneous versus intravenous alemtuzumab for graft-versus-host disease prophylaxis with fludarabine/melphalan-based conditioning in matched unrelated donor allogeneic stem cell transplantation[J].Biol Blood Marrow Transplant,2016,22(3):456-461.
[3]	Nooka AK,Harvey RD,Langston A,et al.Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney:a case series[J].Clin Lymph Myelom Leuk,2014,14(2):59-63.
[4]	Bayraktar UD,Bashir Q,Qazilbash M,et al.Fifty years of melphalan use in hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2013,19(3):344-356.
[5]	Matsuo M,Yamaguchi K,Feril LB,et al.Synergistic inhibition of malignant melanoma proliferation by melphalan combined with ultrasound and microbubbles[J].Ultrason Sonochem,2011,18(5):1218-1224.
[6]	Munier FL,Gaillard MC,Balmer A,et al.Intravitreal chemotherapy for vitreous seeding in retinoblastoma:recent advances and perspectives[J].Saud J Ophthalmol,2013,27(3):147-150.
[7]	Scutaru AM,Wenzel M,Gust R.Bivalent bendamustine and melphalan derivatives as anticancer agents[J].Eur J Med Chem,2011,46(5):1604-1615.
[8]	Zhang N,Cui XY,Zhao XM,et al.Synthesis of melphalan derivatives and their antitumor activities[J].Drug Clin(现代药物与临床),2015,30(2):115-119.
[9]	Chinese Pharmacopoeia Commission.Chinese Pharmacopoeia:part 4(中华人民共和国药典:四部)[S].Beijing:China Medical Science Press,2015:354-356.
[10]	Wang YW,Li QS,Chen XS,et al.Photodissociation reaction of phosgene—first theoretical evidence for the asynchronously concerted three-body decay[J].Acta Chim Sin(化学学报),2003,61(9):1343-1345.